A retrospective study showed that sex has no impact on lung toxicity in NSCLC patients exposed to ALK TKIs (Hwang et al., 2019), but another study suggested that ILD onset in patients receiving crizotinib was affected by sex in the univariate model (Gemma et al., 2019). This evidence concerns the gene ALK and interstitial lung disease.